Locations:
Search IconSearch
February 5, 2024/Cancer

Haploidentical Bone Marrow Transplant Has Durable Engraftment in Patients With Sickle Cell Disease

Two-year event-free survival comparable to matched sibling donor myeloablative transplant

CQD-CHP4445461-hanna-sickle-650×450

Reduced-intensity haploidentical bone marrow transplantation (BMT) for sickle cell disease has resulted in durable engraftment with low mortality, according to the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1507 study.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Presented at the 2023 American Society of Hematology conference, the findings from the adult cohort of the multicenter, phase 2, prospective trial suggest that haploidentical BMT is an important way to increase the donor pool for patients with sickle cell disease and enable access to this lifesaving therapy. Results from the trial’s pediatric cohort are expected by the end of 2024.

“At two years, the overall post-transplant survival rate for adult patients was 95%, and the event-free survival rate was 88%, which are comparable to the outcomes reported after matched sibling donor myeloablative BMT,” says the study’s co-investigator Rabi Hanna, MD, Chair of the Department of Pediatric Hematology, Oncology and Bone Marrow Transplant at Cleveland Clinic.

Sickle cell disease affects approximately 100,000 U.S. patients, making it the most common hemoglobinopathy in the nation. The event-free survival rate is more than 90% in children with sickle cell disease who undergo myeloablative BMT from a matched sibling donor. However, fewer than 17% of patients with the disease have such a donor, and the myeloablative conditioning (MAC) necessary before BMT can be prohibitively toxic in adults with sickle cell disease, who already may have end-organ damage and may not tolerate the intensity of MAC.

BMT CTN 1507 at a glance

BMT CTN 1507 was launched in 2017, after small studies of reduced-intensity human leukocyte antigen (HLA)-haploidentical BMT with post-transplant cyclophosphamide (PTCy) produced encouraging results. Event-free survival at two years after haploidentical BMT was the primary objective. Secondary objectives included determining the impact on clinical and laboratory manifestations of sickle cell disease and other transplant outcomes at two years.

Advertisement

Over a three-year period, 54 eligible participants ages 15 to 46 were enrolled at 19 sites. Of those, 38 completed the study as planned.

Preconditioning consisted of hydroxyurea 30 mg/kg/day on day -70 to day -10 to suppress the bone marrow. The conditioning regimen consisted of thymoglobulin, thiotepa, fludarabine, cyclophosphamide and total body irradiation. Prophylaxis for graft-versus-host disease (GVHD) included PTCy, sirolimus and mycophenolate.

Of the participants, 59.3% were male, 92.6% were Black and 3.7% were Hispanic. The median age was 22.8 years. Eighty-seven percent had hemoglobin SS disease, 74.1% had a Lansky/Karnofsky score of 90 to 100 at baseline, and 75.9% had an HLA match score of 4 of 8.

The most common indications for transplant were recurrent vaso-occlusive pain episodes (38.9%), acute chest syndrome (16.8%) and overt stroke (16.7%). Only 31% of participants achieved the intended dosing of hydroxyurea preconditioning.

Well tolerated, with good rates of engraftment and chimerism

Of the participants, only two had primary graft failure, and one had secondary graft failure before day +100. Cumulative incidence of grades II to IV acute GVHD at day 100 was 26.2% (95% CI: 14.0%-40.2%) — 4.8% for grades III to IV (95% CI: 0.9%-14.4%).

“These results show that a reduced-intensity regimen with thiotepa is very well tolerated, with good rates of engraftment and chimerism and low rates of severe GVHD,” says Dr. Hanna. “The other benefits of this approach are that the technology is well-established, the medication is widely available, and the cost is less than gene therapy, making it accessible to more patients.”

Advertisement

Examining rates of mortality, the investigators noted that two deaths occurred in the first year post-BMT (one due to organ failure and another due to acute respiratory distress syndrome). No deaths occurred in year 2.

“Despite the study’s great outcomes, we still have an approximately 5% mortality rate, and there will be long-term side effects from the chemotherapy,” notes Dr. Hanna. “Ideally we will be able to have a chemotherapy-free or less intense regimen in future studies to enable this life-transformative therapy in more patients.”

Advertisement

Related Articles

DNA
October 10, 2024/Cancer/Research
Blocking YES1 Protein Resensitizes Triple-Negative Breast Cancer to Treatment

Obstructing key protein allows for increased treatment uptake for taxane chemotherapy

Plan of care meeting
October 4, 2024/Cancer/Radiation Oncology
Five Years of Parallel Prospective Plan of Care Reviews

Radiation oncology department finds weekly plan of care meetings have multiple benefits

Radiation therapy
October 2, 2024/Cancer
Partial Breast Irradiation Delivered Daily Well Tolerated in Patients with Early-Stage Breast Cancer

Daily five-fraction partial breast irradiation (PBI) shows similar acute and late toxicity as every other day PBI

Spine cancer
September 30, 2024/Cancer/Radiation Oncology
New Study Supports SBRT as Safe, Effective for Osteosarcoma

Research highlights promising outcomes for treating recurrent and metastatic cases

Genetic sequencing
September 26, 2024/Cancer
AI Can Help Find Trials for Patients with Rare Cancers

Study demonstrates potential for improving access

Ad